Korro Bio is a biopharmaceutical company developing genetic medicines based on RNA editing technology. The company's proprietary platform, Oligonucleotide Promoted Editing of RNA (OPER), enables the design of RNA editing product candidates targeting rare and common diseases. The lead candidate, KRRO-110, is in Phase 1/2 clinical development for Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder affecting the lungs and liver. The company is also advancing programs in Parkinson's disease, amyotrophic lateral sclerosis, and pain indications.
Korro Bio generates revenue through research collaborations and development agreements rather than product sales, as its pipeline remains in early-stage clinical testing. The company maintains a partnership with Novo Nordisk A/S focused on treating cardiometabolic diseases, which represents a significant collaboration channel.
The company operates at a modest scale with 87 full-time employees and is headquartered in Cambridge, Massachusetts. As a clinical-stage biopharmaceutical company with a market capitalization of $0.1 billion, Korro Bio is pre-commercial and operates primarily in the United States market.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-9.37 | $-9.37 | +82.3% | |
| 2023 | $-53.08 | $-53.08 | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-18 | 0000950170-25-040759 | SEC ↗ |
| 2023-12-31 | 2024-03-26 | 0000950170-24-036396 | SEC ↗ |
| 2022-12-31 | 2023-03-10 | 0000950170-23-007140 | SEC ↗ |
| 2021-12-31 | 2022-03-15 | 0000950170-22-003655 | SEC ↗ |
| 2020-12-31 | 2021-03-29 | 0001564590-21-016117 | SEC ↗ |
| 2019-12-31 | 2020-03-26 | 0001564590-20-012977 | SEC ↗ |